Published in Vaccine Weekly, March 3rd, 1997
Sensitive new measures of HIV viral load provide a wealth of information on disease progression. These new tests may be the most sensitive measure of how well an individual is doing in his or her struggle with the AIDS virus.
But data obtained in a Phase II clinical trial of the Genentech candidate HIV vaccine show that a patient's CD4 count remains the best mark of immune function.
"Although HIV replication drives CD4-cell loss, CD4 count is a better marker of immunologic function than plasma HIV-1...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (1997-03-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.